Continuous Glucose Monitoring Device (CGMD) Market is expected to reach US$ 33.21 Billion by 2031

Sensors Segment to Lead Continuous Glucose Monitoring Device (CGMD) Market Based on Product During 2025–2031

According to our new research study on “Continuous Glucose Monitoring Device (CGMD) Market Forecast to 2031 – Global Analysis – by Product, Application, Testing Sites, and End User,” the continuous glucose monitoring device (CGMD) market size is expected to grow from US$ 12.71 billion in 2024 to US$ 33.21 billion by 2031; the market is expected to register a CAGR of 14.9% during 2025–2031. Major factors driving the continuous glucose monitoring device (CGMD) market growth include the rising global prevalence of diabetes, technological advancements in CGM devices, and benefits over conventional glucose monitoring.

Continuous Glucose Monitoring (CGM) devices are wearable technologies that track glucose levels in real time throughout the day and night. They use a small sensor inserted under the skin, typically on the abdomen or arm, which measures glucose in interstitial fluid. Data is transmitted to a display device or smartphone app, allowing users to monitor trends, receive alerts for highs and lows, and make informed decisions about diet, exercise, and insulin use. CGMs are widely used by people with diabetes, and newer models are also being explored for use in wellness monitoring and non-diabetic populations.

Continuous Glucose Monitoring Device (CGMD) Market, by Region, 2024 (%)

Source: The Insight Partners Analysis

Continuous Glucose Monitoring Device (CGMD) Market Analysis Based on Segmental Evaluation:

Based on product, the continuous glucose monitoring device (CGMD) market is segmented into sensors, transmitters, and receivers. In 2024, the sensors segment held a significant continuous glucose monitoring device (CGMD) market share. Sensors remain the technological and economic keystone of continuous glucose monitoring (CGM) systems in diabetes care. These small, wearable components are inserted subcutaneously to continuously measure interstitial glucose levels, typically at 5-minute intervals, transmitting real-time data to receivers or smartphones. The CGM sensor market has seen substantial momentum over the past few years, driven by rapid innovation, growing global diabetes prevalence, and greater adoption among Type 1 and, increasingly, Type 2 diabetes patients. According to data from the International Diabetes Federation (IDF), ~589 million adults (20–79 years) were living with diabetes in 2024. Moreover, by 2050, the projections show that 1 in 8 adults, ~853 million, will be living with diabetes, an increase of 46%. This trend in the growth of diabetes is creating sustained demand for improved glucose monitoring solutions. Unlike traditional fingerstick testing, CGM sensors offer continuous, passive data that enables users to monitor trends, respond proactively to fluctuations, and optimize insulin dosing, significantly reducing the risk of hypoglycemic or hyperglycemic episodes. The ongoing convergence of miniaturization, affordability, and user-centered design is expected to redefine how blood glucose is monitored in clinical and lifestyle settings.

The scope of the continuous glucose monitoring device (CGMD) market report includes an assessment of the market performance in North America, Europe, Asia Pacific, South and Central America, and the Middle East and Africa. In terms of revenue, North America dominated the continuous glucose monitoring device (CGMD) market share in 2024.

The continuous glucose monitoring device (CGMD) market in North America is segmented into the US, Canada, and Mexico. North America is leading the continuous glucose monitoring device (CGMD) market, driven by a combination of increasing prevalence of diabetes, well-established healthcare infrastructure, and rapid adoption of cutting-edge technologies. The continuous glucose monitoring device (CGMD) market in North America is segmented into the US, Canada, and Mexico. North America is expected to lead the continuous glucose monitoring devices market during the forecast period. North America held the most significant share for continuous glucose monitoring devices. The regional market growth is fueled by an increasing number of product launches from leading companies and the presence of key market players.

The US is the most significant contributor to North America's continuous glucose monitoring device (CGMD) market. The increasing prevalence of diabetes drives the demand for continuous glucose monitoring devices in the US. Also, access to modern technology-enabled products favors this country's continuous glucose monitoring devices market. According to statistics released in the American Diabetes Association report in 2021, 38.4 million Americans (11.6%) of the total population had diabetes, including 29.7 million diagnosed and 8.7 million undiagnosed cases. Abbott's FreeStyle Libre 2 is an example of an advanced technology-based continuous glucose monitoring device. It is the longest-lasting integrated continuous glucose monitoring (iCGM) system on the market; it provides glucose readings to the patient every minute. Also, FreeStyle Libre 2 is the only integrated iCGM system available in the US for patients from two age groups, i.e., adults and children aged four or more.

North America dominated the continuous glucose monitoring (CGM) devices market due to technological advancements in healthcare infrastructure and awareness regarding optimizing government and private insurance policies. The advanced infrastructure provides individuals with the topmost clinical facilities that help prevent diseases such as diabetes and cancer.

Early detection assists in identifying and prescribing medication for rare diseases, and CGM devices significantly improve disease prevention. They offer real-time tracking of blood sugar levels and continuously monitor glucose levels in the interstitial fluid to boost the market trend. In addition, Canada also plays a crucial role in providing patients with government initiatives and promoting awareness regarding the advantages of glucose monitoring.

Abbott Laboratories; Dexcom Inc.; Ypsomed Holding AG; Medtronic; F. Hoffmann-La Roche Ltd; Senseonics Holdings Inc; i-SENS Inc.; A. Menarini Diagnostics s.r.l; Tandem Diabetes Care, Inc.; and Medtrum Technologies Inc. are among the leading companies profiled in the continuous glucose monitoring device (CGMD) market report.

Based on product, the continuous glucose monitoring device (CGMD) market is segmented into sensors, transmitters, and receivers. By application, the market is categorized into type 1 diabetes and type 2 diabetes. By testing sites, the market is categorized into fingertip testing and alternate site testing. By end user, the market is segmented into hospitals and clinics, and self or homecare. In terms of geography, the market is categorized into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East and Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com